Cancer Family
Malignant Musculoskeletal Neoplasm
CI-CAN-00000242Explore in graph →
141 active trials5 approved drugs46 evidence items
- NCIt
- C166357
Loading cancer entity…
Cancer Family
CI-CAN-00000242Explore in graph →
Clinical trials
465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (58)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | terminated | Phase 1 | 5 | QSAM Therapeutics, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | terminated | Phase 1 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | terminated | Phase 1 | 2 | AeRang KimOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03041701 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | terminated | Phase 1 / Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials